Back to search

Switzerland· 66510001

Vosevi, Filmtabletten

A sofosbuvir, velpatasvir and voxilaprevir product containing sofosbuvirum, velpatasvirum, voxilaprevirum, registered in Switzerland by Gilead Sciences Switzerland Sàrl and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC J05AP56

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedVosevi, FilmtablettenATCJ05AP56REGISTER NO.66510001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Sofosbuvir, velpatasvir and voxilaprevir is registered in 13 of 19 countries.

Countries holding a registration under ATC J05AP56 (sofosbuvir, velpatasvir and voxilaprevir), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 10 of them publish a price we can compare per daily dose

Sofosbuvir, velpatasvir and voxilaprevir · ATC J05AP56

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of sofosbuvir, velpatasvir and voxilaprevir costs, country by country.

Normalised to the WHO defined daily dose (0.4 g), the median price runs from $447.39 in Switzerland to $1097.10 in Italy — a ×2.5 gap.

  • Switzerland: $447.39 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Sofosbuvir, velpatasvir and voxilaprevir · price per daily dose (0.4 g)

USD · FX 28 Sept 2026

  • IT Italy$1097.10
  • CH Switzerland$447.39
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
sofosbuvirum, velpatasvirum, voxilaprevirum
Manufacturer
Gilead Sciences Switzerland Sàrl
Country
Switzerland (CH)
ATC code
J05AP56
ATC class
Sofosbuvir, velpatasvir and voxilaprevir
Defined daily dose
0.4 g, O
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680665100012
    Fl 28 Stk
    CHF 10389

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Sofosbuvir, velpatasvir and voxilaprevir in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All sofosbuvir, velpatasvir and voxilaprevir products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Vosevi
  • Liechtenstein · Vosevi
  • Norway · Vosevi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/7eefe817-e05d-4875-9fc6-06ae489b5f22
GET /v1/drugs/7eefe817-e05d-4875-9fc6-06ae489b5f22?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "sofosbuvirum 400 mg + velpatasvirum 100 mg + voxilaprevirum 100 mg",
  "valid_from": "2024-10-01",
  "limitations": "[{\"description\":\"Zur Behandlung der chronischen Hepatitis-C-Virus (HCV)-Infektion bei Erwachsenen ohne Zirrhose oder mit kompensierter Zirrhose bei denen ein vorheriges Behandlungsregime mit direkt wirkendem Virostatikum (direct-acting antiviral, DAA) gegen HCV, das einen NS5A-Inhibitor enthielt, versagt hat.<br> \\n• Bei allen Patienten sollte vor Beginn der Behandlung ein HBV-Screening durchgeführt werden. Patienten mit einer positiven HBV-Serologie sollten nach den aktuellen Richtlinien zur klinischen Praxis überwacht und behandelt werden.<br> \\n• Die maximale Vergütungsdauer pro Patient/in ist 12 Wochen (3 Packungen).<br> \\n• Die Verschreibung darf ausschliesslich durch Fachärzte für Gastroenterologie mit Träger des Schwerpunktes Hepatologie oder durch Fachärzte für Infektiologie erfolgen.<br>\\n<br>\\n\\n\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2024-10-01\",\"validTo\":\"2026-09-30\"}]",
  "galenic_form": "Filmtabl 400/100/100",
  "therapeutic_area": null,
  "sl_inclusion_date": "2024-10-01",
  "self_retention_pct": 10
}

See everything about sofosbuvir, velpatasvir and voxilaprevir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.